Government budget balance

IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

Retrieved on: 
Thursday, February 9, 2023
Disease, Movement disorders, Neurodegeneration, Parkinson, Cysteinyl leukotriene receptor 1, Karolinska Institute, Immunomodulation, Trial of the century, Principal, Clinical neuroscience, Per Svenningsson, TSX, Swedish Research Council, Government budget balance, Parkinson's disease, Intellectual property, Lewy body, Clinical trial, Alzheimer's disease, Leukotriene, SCI, Research, Doctor of Philosophy, Pharmaceutical industry, MD, PD, Study

$2 million USD) awarded by the Swedish Research Council, Sweden’s largest governmental research funding body.

Key Points: 
  • $2 million USD) awarded by the Swedish Research Council, Sweden’s largest governmental research funding body.
  • IntelGenx will supply Dr. Svenningsson with both active and placebo films to be used in the 18-month treatment regimen for study participants.
  • Upon completion of the Study, IntelGenx will retain the intellectual property rights and use the findings to further develop its Montelukast VersaFilm® program for Parkinson's disease treatment.
  • 2 Wallin, J; Svenningsson, P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease.

DiagnaMed Holdings Incorporates OpenAI’s ChatGPT into BRAIN AGE™ AI Product Suite

Retrieved on: 
Wednesday, February 1, 2023
Machine learning, Mental health, Education, AI, Digital platform, Lou Ruvo Center for Brain Health, Government budget balance, Sport, Artificial intelligence, BRAIN, Patient, Athlete, CSE, API, Medical imaging

TORONTO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), an artificial intelligence-driven digital health company focusing on improving brain health, today announces that it will incorporate OpenAI’s technology, ChatGPT, in its BRAIN AGE™ Artificial Intelligence (“AI”) Product Suite, which already includes a variety of API interfaces to build AI and machine learning functions, to further enhance the Company’s novel Brain Health Digital Platform to assess overall brain health and presence of cognitive impairment in athletes, and those diagnosed with a mental health and neurodegenerative condition.

Key Points: 
  • TORONTO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED), an artificial intelligence-driven digital health company focusing on improving brain health, today announces that it will incorporate OpenAI’s technology, ChatGPT, in its BRAIN AGE™ Artificial Intelligence (“AI”) Product Suite, which already includes a variety of API interfaces to build AI and machine learning functions, to further enhance the Company’s novel Brain Health Digital Platform to assess overall brain health and presence of cognitive impairment in athletes, and those diagnosed with a mental health and neurodegenerative condition.
  • DiagnaMed’s Brain Health Digital Platform comprises several assessment tools generated rapidly by self-report or clinician-observed measures, each capturing different aspects of brain health to evaluate overall brain health, output a patient risk score, and provide actionable points to develop precision medicine-like, personalized treatment plans and interventions.
  • As part of the BRAIN AGE™ AI Product Suite, the Brain Health Platform will also include unique brain training, games, education, and coaching applications.
  • “Our Brain Health Digital Platform, which is part of our BRAIN AGE™ AI product suite, offers licensed professionals a novel brain health assessment tool, patient risk score, and helpful intervention plans and techniques, incorporating OpentAI’s technology, ChatGPT, with the aim to improve brain health and brain age of patients,” said Fabio Chianelli, Chairman of DiagnaMed.

Mountain of Evidence on Brain Training Keeps Growing

Retrieved on: 
Wednesday, February 1, 2023
MCI, Health, Posit Science Corporation, TCD, Attention, Memory, Government budget balance, TBI, Transcranial direct-current stimulation, COVID, Mindfulness, Dementia, Patient, SAN, Traumatic brain injury, Grammatical mood, Bredesen, GMT, Mini–Mental State Examination, Mayo, Exercise, Research, Schizophrenia, Medical device, Medical imaging

SAN FRANCISCO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The mountain of evidence on the effectiveness on plasticity-based computerized brain training kept growing in 2022, despite the challenges of conducting research during the COVID pandemic, according to Posit Science , the maker of the BrainHQ online brain fitness program.

Key Points: 
  • SAN FRANCISCO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- The mountain of evidence on the effectiveness on plasticity-based computerized brain training kept growing in 2022, despite the challenges of conducting research during the COVID pandemic, according to Posit Science , the maker of the BrainHQ online brain fitness program.
  • In a study among patients with mild Traumatic Brain Injury (TBI), researchers tested Goal Management Training (GMT) against GMT combined with BrainHQ, reporting no significant impact from GMT alone, but a large effect when combined with BrainHQ .
  • Another study of patients with TBI found the BrainHQ produced moderate-to-large gains in both objective and subjective cognitive measures , as compared to a control.
  • Several studies were conducted in older adults with serious cognitive decline, such as Mild Cognitive Impairment (MCI) and Alzheimer’s disease.

Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease

Retrieved on: 
Tuesday, January 24, 2023
Disease, FAS, Food, Safety, Patient, Geriatric Depression Scale, Science, City University of New York, Trial of the century, COVID-19, Cognition, SPA, Behavior, Biomarker, Government budget balance, Headache, Tablet, ADAS-Cog, MMSE, Neuropsychiatry, Cerebrospinal fluid, Degenerative disease, City University, CSF, GDS, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dementia, Mini–Mental State Examination, Alzheimer's disease, CUNY, Urinary tract infection, Data, Brain, Doctor of Philosophy, Pharmaceutical industry, Medical imaging, Vaccine, Copper

AUSTIN, Texas, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced positive top-line Phase 2 results for simufilam, its oral drug candidate for Alzheimer’s disease dementia.

Key Points: 
  • AUSTIN, Texas, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced positive top-line Phase 2 results for simufilam, its oral drug candidate for Alzheimer’s disease dementia.
  • Top-line Results – mean scores, baseline to month 12 (lower is better, except for MMSE):
    Alzheimer’s is a degenerative disease of the brain.
  • ADAS-Cog scores that change minimally (or improve) over 1 year is a highly desirable outcome in a clinical study of mild-to-moderate Alzheimer’s disease.
  • Cassava Sciences is currently evaluating simufilam tablets for Alzheimer’s disease dementia in two Phase 3 clinical studies.

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease

Retrieved on: 
Wednesday, January 18, 2023
Government budget balance, AAIC, Pathology, Safety, LMI, AD, Conference, Alzheimer's disease, Neurodegeneration, Medical imaging, Virtual

PI-2620 was discovered in collaboration between AC Immune and LMI and is developed under a strategic collaboration and exclusive licensing agreement with LMI.

Key Points: 
  • PI-2620 was discovered in collaboration between AC Immune and LMI and is developed under a strategic collaboration and exclusive licensing agreement with LMI.
  • Dr. Andrea Pfeifer, Chief Executive Officer of AC Immune SA, commented: “We are delighted to see LMI launching this pivotal Phase 3 trial of PI-2620, our next generation, potentially best-in-class Tau PET tracer.
  • The ability to detect and quantify aggregated Tau with enhanced sensitivity and specificity, will improve our diagnostic confidence and accelerate clinical development of therapeutic interventions.
  • ; One year longitudinal change of Tau accumulation on [18F]PI-2620 PET in Alzheimer spectrum; Virtual poster presentation; AAIC 2022

Weinberg Elder Law Announces Exclusive Focus on Guardianships and Conservatorships for Vulnerable Populations

Retrieved on: 
Tuesday, January 17, 2023
News, Government budget balance, Ageing, Center for American Progress, Private law, The Hardships of the English Laws in Relation to Wives, Quality of life, Safety, Conservatorship, Friends, American Progress, Health, Cognitive liberty, Britney Spears, Disability, Health insurance

ATLANTA, Jan. 17, 2023 /PRNewswire-PRWeb/ -- Weinberg Elder Law, LLC announced today that the firm is refocusing exclusively on Georgia guardianships and conservatorships. By focusing in this area of what is called fiduciary law, Weinberg will be able to allocate 100% of her resources to protect Georgia's most vulnerable citizens.

Key Points: 
  • Weinberg Elder Law to Focus on Establishing Legal Guardianships and Conservatorships for Cognitively Challenged Georgians.
  • ATLANTA, Jan. 17, 2023 /PRNewswire-PRWeb/ -- Weinberg Elder Law, LLC announced today that the firm is refocusing exclusively on Georgia guardianships and conservatorships.
  • By focusing in this area of what is called fiduciary law, Weinberg will be able to allocate 100% of her resources to protect Georgia's most vulnerable citizens.
  • "After much thought and consideration, Weinberg Elder Law has decided to focus its services exclusively on these types of protective proceedings and the related issues."

When A Child's Concussion is Cause for Concern - Free Webinar

Retrieved on: 
Thursday, January 12, 2023
Rehabilitation, MPH, Pittsburgh, University, Parent, MS, Physical medicine and rehabilitation, Virginia Commonwealth University, University of Pittsburgh, Hack, USAMRMC, Head injury, Trauma, Emergency department, Department of Defense Education Activity, CISD, PPCS, TBI, Adolescence, Research, Government budget balance, Tactical Combat Casualty Care, Concussion, Traumatic brain injury, Brain damage, CTI Education Group, Neurological disorder, MD, Nature, Neurosurgery

GRAND RAPIDS, Mich., Jan. 12, 2023 /PRNewswire/ -- Contact sports, childhood falls, and car accidents can result in concussive injuries with a lasting impact.  Fusion Education Group will host a free webinar about traumatic brain injuries and the potential recovery paths available to children.

Key Points: 
  • GRAND RAPIDS, Mich., Jan. 12, 2023 /PRNewswire/ -- Contact sports, childhood falls, and car accidents can result in concussive injuries with a lasting impact.
  • Fusion Education Group will host a free webinar about traumatic brain injuries and the potential recovery paths available to children.
  • One in four children who suffered a minor head injury is likely to suffer from chronic post-concussion syndrome.
  • Families are encouraged to register for the webinar to discover if the trauma from a head injury is impacting their student's learning.

Autism Science Foundation Awards First Round of Profound Autism Pilot Grants

Retrieved on: 
Wednesday, January 11, 2023
AAC, Infection, Catatonia, Autism Science Foundation, Pain, Communication, Dementia, Sleep, Hospital, Government budget balance, Intellectual disability, Emotional disturbance, Patient, Mouse, Self-Injurious Behavior Inhibiting System, Research, IPad, ASF, Vaccine, Health insurance, Residential care, Autism

NEW YORK, Jan. 11, 2023 /PRNewswire/ -- The Autism Science Foundation (ASF), a nonprofit organization dedicated to funding innovative autism research and supporting families facing autism, today announced the recipients of its inaugural profound autism pilot grants. Four grants will be awarded to researchers for projects examining sleep, neuropsychiatric regression, and self-injurious behaviors, as well as methods to improve access to communications systems for people with profound autism.

Key Points: 
  • This first-of-its-kind funding mechanism supports research on autistic people with the highest support needs, who are demonstrably underrepresented in research
    NEW YORK, Jan. 11, 2023 /PRNewswire/ -- The Autism Science Foundation (ASF), a nonprofit organization dedicated to funding innovative autism research and supporting families facing autism, today announced the recipients of its inaugural profound autism pilot grants.
  • "These new projects will ensure that those across the spectrum are represented in autism research" said ASF Chief Science Officer Dr. Alycia Halladay.
  • Existing studies of sleep in autism have mostly excluded children with profound autism.
  • This regression has been linked to infection in girls with Phelan McDermid Syndrome, a genetic condition associated with profound autism.

Stem Cell Therapy For Long Haul Covid In LA Announced By Springs Rejuvenation

Retrieved on: 
Tuesday, January 24, 2023
COVID-19, Ageing, Cardiovascular disease, Infection, National Center for Health Statistics, Government budget balance, Brain, Timeline of the COVID-19 pandemic, Rejuvenation, Needle, B cell, Pulmonary fibrosis, Respiratory system, Laboratory, Fatigue, Sleep, FDA, Myalgia, Headache, National Center for Regenerative Medicine, Immune system, Patient, Medical statistics, Severe acute respiratory syndrome coronavirus 2, Inflammation, Stem cell, Vaccine, Pharmaceutical industry

The renowned Los Angeles-based stem cell therapy clinic Springs Rejuvenation announces a new therapy for patients suffering from long Covid.

Key Points: 
  • The announcement outlines the clinic's innovative approach to tackling the causes and symptoms of what is known as 'Long Haul Covid'.
  • Stem cell therapy also bolsters the immune system to prevent reinfection and reduce the intensity of symptoms.
  • Covid patients suffering from lung damage can also find relief through the clinic's stem cell solutions.
  • Springs Rejuvenation's stem cell treatments are non-invasive and offer an effective alternative to prescription medication for the relief of chronic disorders.

Life Molecular Imaging and Jubilant Radiopharma announce Neuraceq® availability in Southeast United States

Retrieved on: 
Tuesday, January 10, 2023
Partnership, Drug development, Government budget balance, Research, LMI, Brain, Alzheimer's disease, Dementia, Disease, Patient, SPECT, Physician, PET, Jubilant, Neurodegeneration, Medical imaging

BOSTON, Jan. 10, 2023 /PRNewswire-PRWeb/ -- Life Molecular Imaging (LMI) and Jubilant Radiopharma announce today that both companies have entered into a strategic partnership and licensing agreement providing Jubilant Radiopharma with rights to manufacture and distribute Neuraceq® in the Southeast Region of United States. Jubilant Radiopharma will manufacture Neuraceq® at their PET cyclotron facility which has an adjoining SPECT radiopharmacy in Norcross, GA. The first doses will be available from January 18th, 2023.

Key Points: 
  • BOSTON, Jan. 10, 2023 /PRNewswire-PRWeb/ -- Life Molecular Imaging (LMI) and Jubilant Radiopharma announce today that both companies have entered into a strategic partnership and licensing agreement providing Jubilant Radiopharma with rights to manufacture and distribute Neuraceq® in the Southeast Region of United States.
  • Jubilant Radiopharma will manufacture Neuraceq® at their PET cyclotron facility which has an adjoining SPECT radiopharmacy in Norcross, GA.
  • "With the addition of Jubilant's Norcross Radiopharmacy to our distribution network, Life Molecular Imaging continues to expand the availability of Neuraceq®, an important diagnostic imaging tool for the detection of beta-amyloid plaques in the brain.
  • "It is a great pleasure to have signed this important manufacturing and distribution agreement with Life Molecular Imaging" – declares Renato Leite, President at Jubilant Radiopharmacies.